TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors

Colleen S. Sinclair, Camilo Adem, Ali Naderi, Cheryl L. Soderberg, Michele Johnson, Kangjian Wu, Linda Wadum, Vicki L. Couch, Thomas A. Sellers, Daniel J Schaid, Jeffrey Slezak, Zach Fredericksen, James N. Ingle, Lynn Hartmann, Robert Brian Jenkins, Fergus J Couch

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

The chromosome 17q23 region is frequently amplified in breast tumors. Gain of the region is present in 50% of BRCA1-associated breast tumors and 87% of BRCA2-associated breast tumors. The amplification frequency of the RPS6KB1 and TBX2 oncogenes from this amplicon was compared in 27 BRCA1 and BRCA2 mutant breast tumors, 15 breast tumors from high-risk patients with no BRC1 or BRCA2 mutations, and 62 matched sporadic breast tumor controls. TBX2 was determined to be preferentially amplified and overexpressed in BRCA1 and BRCA2 mutant tumors, whereas RPS6KB1 was not, suggesting a role for TBX2 amplification in the development of BRCA1- and BRCA2-associated breast tumors.

Original languageEnglish (US)
Pages (from-to)3587-3591
Number of pages5
JournalCancer Research
Volume62
Issue number13
StatePublished - Jul 1 2002

Fingerprint

Breast Neoplasms
Oncogenes
Chromosomes
Mutation
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sinclair, C. S., Adem, C., Naderi, A., Soderberg, C. L., Johnson, M., Wu, K., ... Couch, F. J. (2002). TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors. Cancer Research, 62(13), 3587-3591.

TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors. / Sinclair, Colleen S.; Adem, Camilo; Naderi, Ali; Soderberg, Cheryl L.; Johnson, Michele; Wu, Kangjian; Wadum, Linda; Couch, Vicki L.; Sellers, Thomas A.; Schaid, Daniel J; Slezak, Jeffrey; Fredericksen, Zach; Ingle, James N.; Hartmann, Lynn; Jenkins, Robert Brian; Couch, Fergus J.

In: Cancer Research, Vol. 62, No. 13, 01.07.2002, p. 3587-3591.

Research output: Contribution to journalArticle

Sinclair, CS, Adem, C, Naderi, A, Soderberg, CL, Johnson, M, Wu, K, Wadum, L, Couch, VL, Sellers, TA, Schaid, DJ, Slezak, J, Fredericksen, Z, Ingle, JN, Hartmann, L, Jenkins, RB & Couch, FJ 2002, 'TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors', Cancer Research, vol. 62, no. 13, pp. 3587-3591.
Sinclair CS, Adem C, Naderi A, Soderberg CL, Johnson M, Wu K et al. TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors. Cancer Research. 2002 Jul 1;62(13):3587-3591.
Sinclair, Colleen S. ; Adem, Camilo ; Naderi, Ali ; Soderberg, Cheryl L. ; Johnson, Michele ; Wu, Kangjian ; Wadum, Linda ; Couch, Vicki L. ; Sellers, Thomas A. ; Schaid, Daniel J ; Slezak, Jeffrey ; Fredericksen, Zach ; Ingle, James N. ; Hartmann, Lynn ; Jenkins, Robert Brian ; Couch, Fergus J. / TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors. In: Cancer Research. 2002 ; Vol. 62, No. 13. pp. 3587-3591.
@article{1e4f38a8058d472c8a3c394519db5223,
title = "TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors",
abstract = "The chromosome 17q23 region is frequently amplified in breast tumors. Gain of the region is present in 50{\%} of BRCA1-associated breast tumors and 87{\%} of BRCA2-associated breast tumors. The amplification frequency of the RPS6KB1 and TBX2 oncogenes from this amplicon was compared in 27 BRCA1 and BRCA2 mutant breast tumors, 15 breast tumors from high-risk patients with no BRC1 or BRCA2 mutations, and 62 matched sporadic breast tumor controls. TBX2 was determined to be preferentially amplified and overexpressed in BRCA1 and BRCA2 mutant tumors, whereas RPS6KB1 was not, suggesting a role for TBX2 amplification in the development of BRCA1- and BRCA2-associated breast tumors.",
author = "Sinclair, {Colleen S.} and Camilo Adem and Ali Naderi and Soderberg, {Cheryl L.} and Michele Johnson and Kangjian Wu and Linda Wadum and Couch, {Vicki L.} and Sellers, {Thomas A.} and Schaid, {Daniel J} and Jeffrey Slezak and Zach Fredericksen and Ingle, {James N.} and Lynn Hartmann and Jenkins, {Robert Brian} and Couch, {Fergus J}",
year = "2002",
month = "7",
day = "1",
language = "English (US)",
volume = "62",
pages = "3587--3591",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors

AU - Sinclair, Colleen S.

AU - Adem, Camilo

AU - Naderi, Ali

AU - Soderberg, Cheryl L.

AU - Johnson, Michele

AU - Wu, Kangjian

AU - Wadum, Linda

AU - Couch, Vicki L.

AU - Sellers, Thomas A.

AU - Schaid, Daniel J

AU - Slezak, Jeffrey

AU - Fredericksen, Zach

AU - Ingle, James N.

AU - Hartmann, Lynn

AU - Jenkins, Robert Brian

AU - Couch, Fergus J

PY - 2002/7/1

Y1 - 2002/7/1

N2 - The chromosome 17q23 region is frequently amplified in breast tumors. Gain of the region is present in 50% of BRCA1-associated breast tumors and 87% of BRCA2-associated breast tumors. The amplification frequency of the RPS6KB1 and TBX2 oncogenes from this amplicon was compared in 27 BRCA1 and BRCA2 mutant breast tumors, 15 breast tumors from high-risk patients with no BRC1 or BRCA2 mutations, and 62 matched sporadic breast tumor controls. TBX2 was determined to be preferentially amplified and overexpressed in BRCA1 and BRCA2 mutant tumors, whereas RPS6KB1 was not, suggesting a role for TBX2 amplification in the development of BRCA1- and BRCA2-associated breast tumors.

AB - The chromosome 17q23 region is frequently amplified in breast tumors. Gain of the region is present in 50% of BRCA1-associated breast tumors and 87% of BRCA2-associated breast tumors. The amplification frequency of the RPS6KB1 and TBX2 oncogenes from this amplicon was compared in 27 BRCA1 and BRCA2 mutant breast tumors, 15 breast tumors from high-risk patients with no BRC1 or BRCA2 mutations, and 62 matched sporadic breast tumor controls. TBX2 was determined to be preferentially amplified and overexpressed in BRCA1 and BRCA2 mutant tumors, whereas RPS6KB1 was not, suggesting a role for TBX2 amplification in the development of BRCA1- and BRCA2-associated breast tumors.

UR - http://www.scopus.com/inward/record.url?scp=0036645397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036645397&partnerID=8YFLogxK

M3 - Article

C2 - 12097257

AN - SCOPUS:0036645397

VL - 62

SP - 3587

EP - 3591

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 13

ER -